Paul W Armstrong

Biography

Paul Armstrong is University Professor, Department of Medicine (Cardiology) at the University of Alberta, Edmonton, Alberta, Canada and Director of the Canadian VIGOUR Centre (Virtual Coordinating Centre for Global Collaborative Cardiovascular Research). As founding Director of TORCH (TomorrOw's Research Cardiovascular Health Professionals), a Strategic Training Program Initiative and current member of the Executive Advisory Committee, he is committed to the training of cardiovascular researchers. He is a Senior Attending Cardiologist at the University of Alberta Hospital with particular interest and expertise in acute coronary care and heart failure. He is founding and immediate past President of the Canadian Academy of Health Sciences. Dr Armstrong received his medical degree at Queen's University. After post-graduate training both there and at the University of Toronto, he undertook clinical and research training in cardiology at the Massachusetts General Hospital, Harvard Medical School and St. George's Hospital, London, UK. From 1972 until 1984 he served as the first Director of the Coronary Care Unit at the Kingston General Hospital, Queen's University. In 1984, he assumed the position of Chief of Cardiology at St Michael's Hospital and Professor of Medicine at the University of Toronto. From 1993 to 1999, he served as Professor and Chair of the Department of Medicine, University of Alberta. Dr. Armstrong's investigative career has developed along two major lines of inquiry. The first involved the study of the pathophysiology and novel therapeutic approaches of congestive heart failure. The second, now his principal focus, involves the pathophysiology, diagnosis and management of acute coronary syndromes. His role as chair of the international VIGOUR group has lead to multiple leadership and executive positions on large scale international clinical trials of novel strategies in acute coronary syndromes that have helped to transform the care of patients world wide.

Research Interest

Acute Coronary Syndrome, Acute Coronary Syndrome (ACS), Atherosclerosis, Drug: clopidogrel, Drug: enoxaparin, Drug: SCH 530348, Drug: tenecteplase, Member of Executive Committee, Member of the Executive Committee, Member of the Steering Committee, Member Steering Committee, Myocardial Infarction, Myocardial Ischemia, National Coordinator, Procedure: catheterisation, Procedure: primary PCI, Type 2 Diabetes Mellitus